Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. filed its monthly return for the period ended 30 April 2026, confirming that no changes occurred in either its H-share or A-share structure during the month.

H-Shares (HKEX Main Board, stock code 01349) • Issued and registered shares remained at 326.00 million, par value RMB0.10 each. • Registered capital tied to the H-shares stayed at RMB32.60 million. • The company held zero treasury shares and reconfirmed compliance with the HKEX minimum public-float threshold of 5 % for PRC issuers.

A-Shares (STAR Market, Shanghai, stock code 688505) • Issued and registered shares remained at 710.57 million, par value RMB0.10 each. • Corresponding registered capital held steady at RMB71.06 million.

Combined, the group’s total registered share capital stayed unchanged at 1.04 billion shares, equivalent to RMB103.66 million.

The filing also states that during April 2026 there were: • No share issuances, repurchases, or cancellations. • No outstanding share options, warrants, convertible instruments, or other equity-linked agreements.

The monthly return was submitted on 7 May 2026 and signed by company secretary Xue Yan.